Arquivo de Pesquisa Mitocondrial


Uma biblioteca selecionada de publicações científicas revisadas por pares que exploram as fronteiras da energia celular, da resiliência metabólica e da ciência da vitalidade humana.

(+)-Epicatechin and Spinal Cord Injury Recovery

Study Title: Positive Effects of (+)-Epicatechin on Traumatic Spinal Cord Injury Recovery

Citation: Gonzalez-Ruiz et al., 2025 · Biomolecules

What the Study Found: This study evaluated (+)-epicatechin in female Long Evans rats with moderate traumatic spinal cord injury. Animals received either vehicle or (+)-epicatechin beginning 24 hours after injury and were followed for 21 days. Compared with vehicle-treated injured rats, the (+)-epicatechin group showed better locomotor recovery on the BBB scale, including a significantly different recovery slope over time. Protein analysis also suggested protection against injury-associated changes in angiopoietin-1, beclin-1, GFAP, myelin basic protein, NeuN, and neurofilament heavy chain. Together, the results suggest that (+)-epicatechin helped limit several molecular signs of spinal cord damage progression in this experimental model.

What this means in real life: Spinal cord injury involves more than the initial trauma. Secondary damage can affect blood vessels, glial activity, myelin, neurons, and axonal structure over time. In this animal model, (+)-epicatechin appeared to preserve several of these biological markers while supporting better movement recovery. This does not mean (+)-epicatechin is a proven treatment for spinal cord injury in humans, but it adds to the scientific interest around epicatechin-related compounds, neural protection, vascular stability, and recovery biology.

Clinical Relevance: Rat study, moderate traumatic spinal cord injury model, locomotor recovery, neural damage markers, and protein analysis; not human clinical trial evidence.

Related Content: